Changes of central macular thickness post intravitreal ranibizumab and its associated factors among diabetic macular oedema patients
Background: Intravitreal Ranibizumab (IVR) which is an anti-vascular endothelial growth factor (anti-VEGF) has become the preferred treatment option to improve the vision of diabetic macular oedema (DMO) patients. IVR acts by inhibits VEGF-A from binding to its receptors, leading to decreased in vas...
| 主要作者: | |
|---|---|
| 格式: | Thesis |
| 语言: | 英语 |
| 出版: |
2020
|
| 主题: | |
| 在线阅读: | http://eprints.usm.my/51000/ |